Orion Oyj
ORNAV.HE
Cena:
Valuace
50
Růst
45
Zdraví
80
Dokumenty & prezentace
Datum podání
2026
regulated_news
Orion publishes Interim Report for January-September 2026 and holds a webcast on 28 October 2026
14. říj 2026
před 14 dny
regulated_news
125,000 Orion Corporation A shares converted into B shares
7. říj 2026
před 21 dny
regulated_news
Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market
6. říj 2026
před 22 dny
regulated_news
Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company's first biologic candidate to reach clinical testing
5. říj 2026
před 23 dny
regulated_news
Orion Corporation completed share acquisitions
30. zář 2026
před 28 dny
regulated_news
102,000 Orion Corporation A shares converted into B shares
4. zář 2026
před 2 měs.
regulated_news
Orion Corporation to commence acquisition of own shares for its share-based incentive plans
27. srp 2026
před 2 měs.
inside_information
Orion's license partner Tenax Therapeutics' Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint
10. srp 2026
před 3 měs.
semiannual_report
Orion Group Half-Year Financial Report January-June 2026
17. čvc 2026
před 3 měs.
regulated_news
Orion Corporation's financial reporting and Annual General Meeting in 2027
17. čvc 2026
před 3 měs.
regulated_news
45,611 Orion Corporation A shares converted into B shares
15. čvc 2026
před 3 měs.
regulated_news
Orion publishes Half-Year Report for January-June 2026 and holds a webcast on 17 July 2026
3. čvc 2026
před 4 měs.
regulated_news
Orion Pharma announces agreement with Shilpa Medicare for nivolumab biosimilar for European market
30. čvn 2026
před 4 měs.
regulated_news
Orion Pharma's ODM-212 Granted Orphan Designation for the Treatment of Malignant Mesothelioma by the European Commission
23. čvn 2026
před 4 měs.
regulated_news
Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours
30. kvě 2026
před 5 měs.
regulated_news
Orion Pharma to present its first clinical data from Phase 1/2 TEADES trial of TEAD inhibitor ODM-212 at the 2026 ASCO® Annual Meeting
21. kvě 2026
před 5 měs.
regulated_news
105,950 Orion Corporation A shares converted into B shares
15. kvě 2026
před 5 měs.
regulated_news
Orion Animal Health receives US FDA approval for Tessie® (tasipimidine oral solution) for the treatment of noise aversion and separation anxiety in dogs
12. kvě 2026
před 6 měs.
regulated_news
Composition of the Nomination Committee of Orion Corporation
27. dub 2026
před 6 měs.
Kvartální
Orion Group Interim report January-March 2026
23. dub 2026
před 6 měs.
regulated_news
Orion Pharma initiates TEADCO Phase 1b/2 basket trial evaluating ODM-212 in combination with standard of care treatments in patients with select advanced solid tumours
23. dub 2026
před 6 měs.
regulated_news
Orion Pharma's ODM-212 Granted Orphan Drug Designation in Mesothelioma by the US FDA
20. dub 2026
před 6 měs.
regulated_news
Orion publishes Interim Report for January-March 2026 and holds a webcast on 23 April 2026
10. dub 2026
před 7 měs.
regulated_news
Change in Orion Group Executive Team as of 8 April 2026 - Berkeley Vincent appointed Executive Vice President, Innovative Medicines
1. dub 2026
před 7 měs.
regulated_news
Decisions taken by Orion Corporation's Annual General Meeting and Board of Directors' organising meeting on 24 March 2026
24. bře 2026
před 7 měs.
regulated_news
Peace through well-being: Orion and CMI - Martti Ahtisaari Peace Foundation announce partnership
18. bře 2026
před 7 měs.
Výroční
Orion Group Financial Statement documents 2025 and Remuneration Report published
27. úno 2026
před 8 měs.
regulated_news
The Board of Directors of Orion Corporation decided on a new plan period for the Long-term Incentive program for the company's key persons
12. úno 2026
před 8 měs.
regulated_news
Notice to the Annual General Meeting of Orion Corporation
12. úno 2026
před 8 měs.
Kvartální
Orion Group Financial Statement Release January-December 2025
12. úno 2026
před 8 měs.
regulated_news
62,752 Orion Corporation A shares converted into B shares
3. úno 2026
před 9 měs.
regulated_news
Orion publishes Financial Statement Release for 2025 and holds a webcast on 12 February 2026
30. led 2026
před 9 měs.
regulated_news
182,827 Orion Corporation A shares converted into B shares
16. led 2026
před 9 měs.
regulated_news
Recommendation by the Orion Nomination Committee on the proposals to be presented to the 2026 Annual General Meeting
15. led 2026
před 9 měs.
regulated_news
Orion updates time estimate for the potential related to the annual Nubeqa® net sales recorded by Orion
14. led 2026
před 9 měs.
inside_information
Inside information: Orion provides outlook for 2026 and estimates that the annual Nubeqa® net sales recorded by Orion has potential to exceed EUR 1 billion in the future
14. led 2026
před 9 měs.
regulated_news
Orion Pharma announces the initiation of TEADES Phase 2 trial of ODM-212 in Malignant Pleural Mesothelioma (MPM) and Epithelioid Hemangioendothelioma (EHE)
8. led 2026
před 10 měs.
2025
inside_information
Inside information: Orion to receive EUR 180 million milestone and updates full-year outlook for 2025
3. pro 2025
před 11 měs.
regulated_news
71,498 Orion Corporation A shares converted into B shares
27. lis 2025
před 11 měs.
regulated_news
Orion receives award for international growth from the President of the Republic of Finland
14. lis 2025
před 11 měs.
Kvartální
Orion Group Interim Report January-September 2025
28. říj 2025
před 1 r.
regulated_news
49,164 Orion Corporation A shares converted into B shares
24. říj 2025
před 1 r.
regulated_news
Orion and Abzena announce exclusive commercial license for Abzena's antibody
23. říj 2025
před 1 r.
regulated_news
Orion publishes Interim Report for January-September 2025 and holds a webcast on 28 October 2025
14. říj 2025
před 1 r.
regulated_news
Orion's phase 2 study of ODM-105 in insomnia did not meet primary goal
30. zář 2025
před 1 r.
regulated_news
80,802 Orion Corporation A shares converted into B shares
19. zář 2025
před 1 r.
regulated_news
337,000 Orion Corporation A shares converted into B shares
20. srp 2025
před 1 r.
regulated_news
Darolutamide receives EU approval in third indication for patients with advanced prostate cancer
21. čvc 2025
před 1 r.
semiannual_report
Orion Group Half-Year Financial Report January-June 2025
18. čvc 2025
před 1 r.
regulated_news
Orion Corporation's financial reporting and Annual General Meeting in 2026
18. čvc 2025
před 1 r.
inside_information
Inside information: Orion upgrades full-year outlook for 2025
9. čvc 2025
před 1 r.
regulated_news
Orion publishes Half-Year Financial Report for January-June 2025 and holds a webcast on 18 July 2025
4. čvc 2025
před 1 r.
regulated_news
141,959 Orion Corporation A shares converted into B shares
23. čvn 2025
před 1 r.
regulated_news
CHMP recommends third indication for darolutamide for patients with advanced prostate cancer
20. čvn 2025
před 1 r.
regulated_news
Orion and Glykos announce the extension of their research collaboration and licensing agreement for the development of next-generation ADCs
17. čvn 2025
před 1 r.
regulated_news
U.S. FDA approves third indication of darolutamide for patients with advanced prostate cancer
3. čvn 2025
před 1 r.
regulated_news
Orion announces agreement with Shilpa Medicare for Recombinant Human Albumin for European market
23. kvě 2025
před 1 r.
regulated_news
Orion to host Capital Markets Day today, 22 May 2025, in Helsinki
22. kvě 2025
před 1 r.
regulated_news
Orion's collaborator, MSD, expands clinical development program for opevesostat to women's cancers
21. kvě 2025
před 1 r.
regulated_news
301,521 Orion Corporation A shares converted into B shares
2. kvě 2025
před 1 r.
regulated_news
Orion and Criceto Announce a License Agreement for APORON®, an Innovative Apomorphine Spray to Treat OFF Episodes in Parkinson's Disease
25. dub 2025
před 2 r.
regulated_news
Composition of the Nomination Committee of Orion Corporation
24. dub 2025
před 2 r.
Kvartální
Orion Group Interim Report January-March 2025
23. dub 2025
před 2 r.
regulated_news
Invitation to Orion's Capital Markets Day on 22 May 2025
22. dub 2025
před 2 r.
regulated_news
Statutory negotiations at Orion's R&D unit in Turku, Finland have been concluded
15. dub 2025
před 2 r.
regulated_news
The Helsinki Court of Appeal sentenced a member of Orion's Board of Directors to a fine for a securities market information offence
10. dub 2025
před 2 r.
regulated_news
Orion publishes Interim Report for January-March 2025 and holds a webcast on 23 April 2025
9. dub 2025
před 2 r.
regulated_news
Orion Corporation: Organising meeting of the Board of Directors
3. dub 2025
před 2 r.
regulated_news
Decisions taken by Orion Corporation's Annual General Meeting on 3 April 2025
3. dub 2025
před 2 r.
regulated_news
Pharmaceutical industry delivers value proposition to Finnish Government: billions to be invested by 2030
21. bře 2025
před 2 r.
Výroční
Orion Group Financial Statement documents 2024 and Remuneration Report published
11. bře 2025
před 2 r.
regulated_news
Orion to open new Biologics R&D Centre in Cambridge, UK in 2025 to support global growth strategy, considers reorganizing some work in Turku
10. bře 2025
před 2 r.
regulated_news
Orion and Aiforia extend collaboration to preclinical study evaluations
5. bře 2025
před 2 r.
regulated_news
Orion Corporation: The Board of Directors of Orion Corporation decided on incentive programs for the company's key persons
25. úno 2025
před 2 r.
regulated_news
Notice to the Annual General Meeting of Orion Corporation
25. úno 2025
před 2 r.
Kvartální
Orion Group Financial Statement Release January-December 2024
25. úno 2025
před 2 r.
regulated_news
EU's Urban Wastewater Treatment Directive could lead to additional costs of nearly EUR 1 billion in Finland alone, posing a serious threat to medicine availability
13. úno 2025
před 2 r.
regulated_news
Save the Date: Orion's Capital Markets Day on 22 May 2025
10. úno 2025
před 2 r.
regulated_news
Orion and Invenra announce discovery service and commercial license agreement to develop innovative bispecific antibody cancer therapeutics
30. led 2025
před 2 r.
regulated_news
Orion publishes Financial Statement Release for 2024 and holds a webcast on 25 February 2025
28. led 2025
před 2 r.
inside_information
Inside information: Orion upgrades full-year outlook for 2024 and provides preliminary information on financial performance for 2024
15. led 2025
před 2 r.
regulated_news
Recommendation by the Orion Nomination Committee on the proposals to be submitted to the 2025 Annual General Meeting
15. led 2025
před 2 r.
regulated_news
79,345 Orion Corporation A shares converted into B shares
13. led 2025
před 2 r.
regulated_news
Orion's collaboration partner Bayer submits application in China for third indication of darolutamide
7. led 2025
před 2 r.
2024
regulated_news
Orion and Marinus terminate agreement for ganaxolone in Europe
30. pro 2024
před 2 r.
regulated_news
CORRECTION: Change in Orion Group Executive Management Board as of 1 June 2025 - Mikko Kemppainen appointed General Counsel
19. pro 2024
před 2 r.
regulated_news
Change in Orion Group Executive Management Board as of 1 June 2025 - Mikko Kemppainen appointed General Counsel
19. pro 2024
před 2 r.
regulated_news
Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics
18. pro 2024
před 2 r.
regulated_news
Penalty payment to a member of Orion's Board of Directors for delay in notifying managers' transaction
12. pro 2024
před 2 r.
regulated_news
142,701 Orion Corporation A shares converted into B shares
27. lis 2024
před 2 r.
regulated_news
Orion Research Foundation grants EUR 1,109,000 for research in 2025
22. lis 2024
před 2 r.
regulated_news
Orion and Alligator Bioscience amend their agreement concerning two bispecific antibodies
19. lis 2024
před 2 r.
Kvartální
Orion Group Interim Report January-September 2024
29. říj 2024
před 2 r.
inside_information
Inside information: Orion terminates ODM-111 development program due to narrow therapeutic window of the molecule
24. říj 2024
před 2 r.
regulated_news
Orion publishes Interim Report for January-September 2024 and holds a webcast on 29 October 2024
15. říj 2024
před 2 r.
regulated_news
Orion's collaboration partner Bayer submits application for third indication of darolutamide in the EU
14. říj 2024
před 2 r.
regulated_news
Orion's near-term climate targets approved by the Science Based Targets initiative
30. zář 2024
před 2 r.
regulated_news
Orion's collaboration partner Bayer submits application to U.S. FDA for third indication of darolutamide which has become the first ever Orion-originated blockbuster
26. zář 2024
před 2 r.
regulated_news
213,285 Orion Corporation A shares converted into B shares
20. zář 2024
před 2 r.
inside_information
Inside information: Orion upgrades full-year outlook for 2024
11. zář 2024
před 2 r.
regulated_news
44,767 Orion Corporation A shares converted into B shares
14. srp 2024
před 2 r.
semiannual_report
Orion Group Half-Year Financial Report January-June 2024
8. srp 2024
před 2 r.
regulated_news
Orion Corporation's financial reporting and Annual General Meeting in 2025
8. srp 2024
před 2 r.
regulated_news
Orion publishes Half-Year Financial Report for January-June 2024 and holds a webcast on 8 August 2024
25. čvc 2024
před 2 r.
inside_information
Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer meets primary endpoint
17. čvc 2024
před 2 r.
inside_information
Inside information: Orion and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer
1. čvc 2024
před 2 r.
inside_information
Inside information: Orion upgrades full-year outlook for 2024
1. čvc 2024
před 2 r.
regulated_news
Orion Corporation: Change in Orion Group Executive Management Board as of 31 May 2025
7. kvě 2024
před 2 r.
regulated_news
Composition of the Nomination Committee of Orion Corporation
26. dub 2024
před 3 r.
Kvartální
Orion Group Interim Report January-March 2024
25. dub 2024
před 3 r.
regulated_news
Orion publishes Interim Report for January-March 2024 and holds a webcast on 25 April 2024
11. dub 2024
před 3 r.
regulated_news
Change in Orion Group Executive Management Board: change in Orion's group-level functions
22. bře 2024
před 3 r.
regulated_news
The change negotiations concerning Orion's Kuopio plant have been concluded - the company has decided to continue to explore the outsourcing of production at the plant
22. bře 2024
před 3 r.
regulated_news
Orion Corporation: Organising meeting of the Board of Directors
20. bře 2024
před 3 r.
regulated_news
Decisions taken by Orion Corporation's Annual General Meeting on 20 March 2024
20. bře 2024
před 3 r.
Výroční
Orion Group Financial Statement documents 2023, Corporate Governance Statement and Remuneration Report published
26. úno 2024
před 3 r.
regulated_news
Orion and Save the Children Finland announce cooperation to promote well-being of children in Finland and globally
22. úno 2024
před 3 r.
regulated_news
Orion to investigate the possible outsourcing of its pharmaceutical production in Kuopio, Finland
19. úno 2024
před 3 r.
regulated_news
Notice to the Annual General Meeting of Orion Corporation
13. úno 2024
před 3 r.
Kvartální
Orion Group Financial Statement Release January-December 2023
13. úno 2024
před 3 r.
Pro zvolenou kategorii nemáme žádné dokumenty.
